Resources | NITAG RESOURCE CENTER

2015 ∙ Marangu, D. Kovacs, S. Walson, J. Bonhoeffer, J. Ortiz, J. R. John-Stewart, G. Horne, D. J.

Wheeze as an adverse event in pediatric vaccine and drug randomized controlled trials: A systematic review

2015

Mosquirix: Opinion on medicine for use outside EU

2015 ∙ STIKO

Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease

2015 ∙ Milagritos D. Tapia, Samba O. Sow, Fadima Cheick Haidara, Fatoumata Diallo, Moussa Doumbia, Godwin C. Enwere, Gandhali Paranjape, Jacques Hervé, Marie-Pierre Préziosi

A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians

2015 ∙ Andromachi Karachaliou, Andrew J. K. Conlan, Marie-Pierre Préziosi, Caroline Trotter

Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt

2015 ∙ WHO

Meningococcal A conjugate vaccine: updated guidance

2015 ∙ RTS,S Clinical Trials Partnership

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

2015 ∙ SAGE

Safety of pertussis vaccines in immunocompetent infants and children

2015 ∙ CAVEI

Chile - Standard Operating Procedure of the National Committee on Vaccines and Immunization Strategies

2015 ∙ SAGE

Duration of protection conferred by MenA conjugate vaccination in immunocompetent children (3 to 24 months of age) against serogroup A meningococcal disease